CLINICAL TRIALS PROFILE FOR ZAVEGEPANT HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for zavegepant hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04346615 ↗ | Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen | Recruiting | Biohaven Pharmaceuticals, Inc. | Phase 2/Phase 3 | 2020-04-25 | The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, ARDS, requirement for supplemental oxygenation, artificial ventilation or death in patients with COVID-19 on supplemental oxygen. * BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use. |
| NCT04408794 ↗ | Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine | Active, not recruiting | Biohaven Pharmaceuticals, Inc. | Phase 2/Phase 3 | 2020-06-29 | The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. * BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use. |
| NCT04571060 ↗ | Randomized Trial in Adult Subjects With Acute Migraines | Completed | Biohaven Pharmaceuticals, Inc. | Phase 3 | 2020-10-27 | The purpose of this study is to test the safety and efficacy of BHV-3500 versus placebo in the acute treatment of moderate or severe migraine. |
| NCT04804033 ↗ | A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention | Recruiting | Biohaven Pharmaceutical Holding Company Ltd. | Phase 2/Phase 3 | 2021-03-26 | The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month. |
| NCT04987944 ↗ | Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma | Recruiting | Biohaven Pharmaceuticals, Inc. | Phase 1 | 2021-10-18 | This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for zavegepant hydrochloride
Condition Name
Clinical Trial Locations for zavegepant hydrochloride
Trials by Country
Clinical Trial Progress for zavegepant hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for zavegepant hydrochloride
Sponsor Name
